Clinical Edit Criteria Proposal

Drug/Drug Class:	**SNRI Clinical Edit**
Date:	**June 6, 2012**
Prepared for:	
Prepared by:	**MO HealthNet**

☐ **New Criteria** ☒ **Revision of Existing Criteria**

Executive Summary

Purpose:

Ensure appropriate and prudent use serotonin-norepinephrine reuptake inhibitors (SNRIs) medications within the MO HealthNet Pharmacy program.

Why was this Issue Selected:

Patient safety is at the heart of MO HealthNet administration and Pharmacy management decision-making. Protecting patient safety in the Pharmacy program includes assessing for utilization of the SNRIs medications. By using medical evidence guidelines, a new clinical edit can help to flag potentially dangerous duplicate and high dose therapy for these agents. Additionally, some participants are cared for by multiple prescribers and have medications filled at different pharmacies. Without a clinical edit capability it is almost impossible to prevent duplication within a drug class, dangerous drug interactions, or overmedication. The clinical edit would not replace medical practice. T**he edit helps to provide an "early warning alert" to the pharmacist filling the prescription and the prescribing physician.** Even if the edit is "triggered" and the physician wishes to over-ride the process for medically necessary reasons, as is presently true for all other drug classes the drug can be approved with further medical input through direct communication with the MHD Hotline. As the clinical edits are phased in, compliance and efficacy with existing medications are always taken into account, helping to ensure a smooth transition for current participants.

Setting & Population:

All Patients

Type of Criteria:

☐ **Increased risk of ADE** ☐ **Non-Preferred Agent**

☒ **Appropriate Utilization** ☐ **Other:**

Data Sources:

☐ **Only administrative databases** ☒ **Databases + Prescriber-supplied**

Program-specific information:



Setting & Population

- Drug/drug class for review: SNRI Antidepressants
- Age range: All patients
- Gender: males and females

Approval Criteria

- Appropriate diagnosis (see diagnosis table – Appendix A)
  - **Cymbalta Only** – Chronic Musculoskeletal Pain**
    - **Osteoarthritis**
    - **Lower Back Pain**
- Doses not exceeding recommended maximum doses (see Table 1)
- Documented compliance to current therapy regimen (adults – 90 days of therapy out of the most recent 120 days)

Approval Diagnoses (Appendix A)				
Condition	**Submitted ICD-9 Diagnoses**	**Inferred Drugs**	**Date Range**	**Client Approval**
Depression	311, 309.0-309.4, 289.0,300.4	--	720 days	
Bipolar	296.0 – 296.99	--	720 days	
Anxiety	300.00	--	720 days	
Diabetic Peripheral Neuropathy	250.6, 356.9-357.2	--	720 days	
Fibromyalgia	729.1	--	720 days	
Panic Disorder	300.01	--	720 days	
Osteoarthritis**	**715.0 – 715.9, 715.89, 721.90**	**--**	**720 days**	
Lumbago**	**724.2, 722.10**	**--**	**720 days**	

****Approval codes for Cymbalta only**

Denial Criteria

- Use of more than two SNRI medications for more than 60 of the past 90 days
- For under 18 years:
  - Use of 2 or more SNRI medications for more than 30 days
- Use of SNRI medications for children under age 5 years
- Concurrent use of more than 1 SSRI agent **and 1 SNRI agent** for more than 30 days
- Use of SNRI medications at higher than recommended max dose for more than 45 days (see Table 1)
- Lack of approval criteria

Required Documentation

Laboratory results:	☐	Progress notes:	☐
MedWatch form:	☐		

Disposition of Edit

- **Denial:** Edit 682 "Clinical Edit"

References

1. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2011.
2. Facts and Comparisons; 2011.
3. USPDI, Micromedex, 2011.
4. Clinical Pharmacology Online, 2011.
5. Missouri Behavioral Pharmacy Management Program, CNS/CMT; 2010.

SNRI Antidepressants Table 1

Brand Name	Generic Name	Current Adult Daily Dose	Recommended Adult Daily Dose
Cymbalta	Duloxetine	150 mg	**120 mg**
Effexor	Venlafaxine	400 mg	**375 mg**
Pristiq	Desvenlafaxine	450 mg	**400 mg**
Effexor XR	Venlafaxine	275 mg	**225 mg**